Healthcare / BiotechnologyWarsaw
$4.10
-0.07 (-1.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $9.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$352M
P/E
80.7x
↑EV/EBITDA
7.7x
↓ROE
0.6%
↑Gross Margin
32.5%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.6%
FCF CAGR
-28.8%
FCF margin
3.4%
FCF / Net income
2.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $282.5M · net income $3.4M · FCF $9.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $282.5M | $282.5M | $207.8M | $181.6M | $233.2M |
| Net Income | $3.4M | $3.4M | $-15.7M | $2.3M | $1.4M |
| EBITDA | $51.4M | $51.4M | $31.9M | $50.5M | $47.2M |
| EPS | 0.04 | 0.04 | -0.18 | 0.03 | 0.02 |
| Gross Margin | 32.5% | 32.5% | 31.2% | 40.1% | 41.1% |
| Operating Margin | 4.9% | 4.9% | -2.8% | -1.7% | 11.2% |
| Net Margin | 1.2% | 1.2% | -7.5% | 1.3% | 0.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.10 | 0.11 | 0.13 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.6M | $9.6M | $25.1M | $-4.5M | $26.5M |
| Returns | |||||
| ROE | 0.6% | 0.6% | -2.7% | 0.4% | 0.2% |
| Valuation | |||||
| P/E | 80.70 | 80.70 | — | 121.00 | 171.75 |
| EV/EBITDA | 7.70 | 7.70 | 10.05 | 7.46 | 7.67 |
| P/B | 0.58 | 0.58 | 0.46 | 0.51 | 0.49 |
| Growth & Yield | |||||
| Revenue Growth | 36.0% | 36.0% | 14.4% | -22.1% | — |
| EPS Growth | 121.7% | 121.7% | -708.0% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
109.6%
EPS terminal req.
$0.36
Spread vs growth
12.0%
5Y implied EPS CAGR
62.0%
EPS terminal req.
$0.44
Spread vs growth
59.7%
10Y implied EPS CAGR
33.5%
EPS terminal req.
$0.71
Spread vs growth
88.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → 0.04
Residual
-3.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.